
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems Inc is projected to experience significant revenue growth, with total revenues anticipated to reach $338.7 million by 2032, up from $82.3 million in 2025. The company has demonstrated consistent quarter-over-quarter growth in HEPZATO-related revenues, indicating strong market adoption since the product's launch, with a notable 37% increase from $10.0 million in 3Q24 to $13.7 million in 4Q24. Additionally, Delcath's strategic focus on expanding its business in European markets, alongside successful new site activations, is expected to support ongoing financial performance and enhance its growth potential in 2025.
Bears say
Delcath Systems Inc has been facing significant operational challenges, evidenced by increasing costs associated with the research and development of its Melphalan Hydrochloride product and Hepatic Delivery System, which may adversely impact its profitability margins. Furthermore, the company has not demonstrated a considerable revenue growth trajectory, raising concerns about its market position and sustainability in the competitive oncology sector. Finally, the financial reports indicate a reliance on substantial external funding, which could be a risk factor given the volatility in investor sentiment and market conditions.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares